Developer docs
API playgroundTry for free, no card

Search company profiles

Eccogene

Full company profile

uuid0000erg

Namestring
Eccogene
Legal namestring
Eccogene, Inc.
Websiteurl
eccogene.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Eccogene, Inc. is a clinical-stage biopharmaceutical company founded in 2018 by drug-discovery veterans from Lilly China R&D and GlaxoSmithKline. Headquartered in Cambridge, Massachusetts with research operations in Shanghai's Zhangjiang district, Eccogene focuses on discovering and developing oral small molecule therapeutics for cardiometabolic and inflammatory diseases — principally obesity, type 2 diabetes, MASH/NASH, dyslipidemia, and osteoarthritis pain. The company's core technology platform is a translational small molecule discovery engine that targets metabolic disease pathways including GLP-1, THR-β, SSAO/VAP-1, GIP, and amylin, with design priorities of oral once-daily dosing, improved PK/PD and safety profiles, and combinability with GLP-1 receptor agonists.

The pipeline is anchored by ECC5004 (elecoglipron/AZD5004), an internally discovered, once-daily oral small molecule GLP-1 receptor agonist that has demonstrated best-in-class potential in preclinical and Phase 1 data and is now in AstraZeneca's hands for Phase 2b/3 development. Wholly-owned clinical assets include ECC4703, a selective liver-targeting THR-β full agonist in Phase 2a for MASH and as an adjunct to semaglutide in obesity (MIST trial), and ECC0509, a peripherally restricted SSAO/VAP-1 inhibitor in Phase 2a for MASH and osteoarthritis pain. Preclinical programs target GIP, amylin, and a unimolecular poly-agonist (UPA) engaging GLP-1R, GIPR, and amylin receptors.

Eccogene operates an asset-light licensing business model, monetizing its pipeline through upfront payments, development and regulatory milestones, and royalties from pharmaceutical partners rather than building its own commercial organization. The AstraZeneca license for ECC5004 generated a $185 million upfront in November 2023 and a $60 million milestone in October 2024, with up to $1.825 billion in additional potential milestones and tiered royalties; Eccogene retains co-development and co-commercialization rights in China. The company is funded by a syndicate of healthcare-focused venture investors including Delos Capital, Oriza Seed Capital, New Alliance Capital, and Zhangjiang Healthcare Venture Capital, and has secured multiple FDA IND clearances across its pipeline.

Short descriptiontext

Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory diseases. Its pipeline includes an oral GLP-1 receptor agonist licensed to AstraZeneca plus wholly-owned THR-β and SSAO programs for obesity, type 2 diabetes, and MASH.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule therapeutics, cardiometabolic drug discovery, oral GLP-1 agonists, metabolic disease treatments, anti-obesity pharmaceuticals
Industry4 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cardiometabolic Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Eccogene generates revenue through licensing agreements with pharmaceutical partners, receiving upfront payments, milestone payments tied to clinical, regulatory, and commercial achievements, and tiered royalties on net product sales. The AstraZeneca deal for ECC5004 includes $185 million upfront, up to $1.825 billion in future milestones, and royalty payments.

eccogene.com
2Series B Equity Financing
TypeLicensing Royalties
Description

CNY 180 million (approximately $25 million) Series B financing co-led by New Alliance Capital and Zhangjiang Healthcare Venture Capital, with participation from Rockbleu Capital, YuFu Investment, Huajin Capital, Elikon Venture, Delos Capital, Oriza Seed Capital, and Qingsong Capital.

eccogene.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Eccogene discovers and develops oral small molecule drug candidates for cardiometabolic and inflammatory diseases, with a pipeline targeting obesity, type 2 diabetes, MASH/NASH, dyslipidemia, and OA pain. Its lead asset ECC5004 (elecoglipron/AZD5004), an oral once-daily small molecule GLP-1 receptor agonist, has been exclusively licensed to AstraZeneca for global development and commercialization. The company also independently advances ECC4703 (THR-β full agonist), ECC0509 (SSAO inhibitor), and preclinical programs targeting GIP, amylin, and a unimolecular poly-agonist.

Differentiator
Functional benefit
Problem solved
Product and service6 records
1ECC5004 / Elecoglipron (AZD5004)
CategoryOral GLP-1 Receptor Agonist (Small Molecule)
Description

Once-daily, low-dose oral small molecule GLP-1 receptor agonist discovered internally by Eccogene; best-in-class potential with favorable safety/tolerability and clinically meaningful weight reduction in Phase 1b. Licensed to AstraZeneca globally (all territories except China) for development and commercialization across obesity, type 2 diabetes, and related cardiometabolic indications; Eccogene retains co-development and co-commercialization rights in China.

2ECC4703
CategoryTHR-β Full Agonist (Small Molecule)
Description

β-selective, liver-targeting thyroid hormone receptor (THR-β) full agonist with once-daily oral dosing, designed for MASH/NASH, dyslipidemia, and weight management (including combination use with GLP-1 receptor agonists). Demonstrated superiority over partial agonist MGL-3196 in preclinical studies and favorable Phase 1 safety, PK/PD, and target engagement.

3ECC0509
CategorySSAO/VAP-1 Inhibitor (Small Molecule)
Description

Highly selective, peripherally distributed small molecule inhibitor of SSAO/VAP-1 with minimal brain penetration, developed for NASH/MASH and osteoarthritis pain, with favorable safety and target engagement profiles demonstrated in Phase 1.

4GIP Program (Small Molecule GIPR Agonist)
CategoryGIP Receptor Agonist (Small Molecule, Preclinical)
Description

Preclinical small molecule GIP receptor agonist program targeting metabolic diseases, part of Eccogene's broader pipeline exploring proven metabolic pathways beyond GLP-1.

5Amylin Program (Small Molecule AmylinR Agonist)
CategoryAmylin Receptor Agonist (Small Molecule, Preclinical)
Description

Preclinical small molecule amylin receptor agonist program targeting metabolic diseases, designed to complement GLP-1-based therapies for enhanced metabolic benefits.

6UPA Program (Unimolecular Poly-agonist)
CategoryUnimolecular Poly-agonist (Preclinical)
Description

Preclinical unimolecular poly-agonist that engages GLP-1R, GIPR, and Amylin receptors in a single molecular entity, designed to deliver enhanced metabolic benefits versus single-pathway agonists.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-11-09
Description

Eccogene entered an exclusive license agreement with AstraZeneca in November 2023 for ECC5004/AZD5004, an oral small molecule GLP-1 receptor agonist. AstraZeneca received exclusive global rights for development and commercialization in all territories except China, where Eccogene retains co-development and co-commercialization rights. Eccogene received $185 million upfront and is eligible for up to $1.825 billion in future clinical, regulatory, and commercial milestones, plus tiered royalties on net sales. AstraZeneca is advancing ECC5004 (now called elecoglipron or AZD5004) through Phase 2b and Phase 3 trials.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

AstraZeneca has established collaborations with partners including Eccogene, CSPC Pharmaceuticals, the SOPHIA Consortium, FNIH, and Shanghai Institute of Materia Medica to advance next-generation therapies for obesity and type 2 diabetes.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing oral small molecule GLP-1 receptor agonists (GSBR-1290) for obesity and type 2 diabetes. Direct competitor in oral GLP-1 RA space with similar best-in-class positioning strategy.

TypeDirect peer
Description

Clinical-stage biotech developing VK2735 (oral and subcutaneous GLP-1/GIP dual agonist) for obesity. Comparable pipeline focus on oral and injectable cardiometabolic candidates with similar licensing/partnering strategy.

TypeDirect peer
Description

Clinical-stage biotech developing TERN-601 (oral GLP-1 RA) and other oral small molecules for obesity. Direct peer in oral GLP-1 development with similar China-related operational footprint.

TypeDirect peer
Description

Developed resmetirom (Rezdiffra), the first FDA-approved THR-β agonist for MASH. Directly relevant peer for Eccogene's ECC4703 THR-β agonist program targeting the same MASH/NASH indication.

TypeRegional player
Description

China-based biopharmaceutical company developing mazdutide (IBI362), a GLP-1/glucagon dual agonist for diabetes and obesity. Regional peer in cardiometabolic space with comparable China commercial footprint and oral/injectable metabolic pipeline.

TypeDirect peer
Description

Clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH. Comparable peer in MASH/NASH therapeutics with similar Phase 2/3 development path and licensing economics potential.

TypeBroad incumbent
Description

Large pharmaceutical company developing danuglipron, an oral small molecule GLP-1 RA for obesity and diabetes. Broad incumbent in the same oral GLP-1 space with massive commercialization capabilities competing with Eccogene's ECC5004.

TypeBroad incumbent
Description

Global pharmaceutical leader with orforglipron (oral GLP-1 RA) in late-stage development and established injectable franchise (semaglutide via Mounjaro/Zepbound competitor Novo Nordisk). Broad incumbent whose R&D lineage includes Eccogene's founders.

TypeDirect peer
Description

Clinical-stage biotech developing pegozafermin (FGF21 analog) for MASH. Comparable peer in MASH/NASH with similar clinical-stage positioning and licensing partnership potential.

TypeRegional player
Description

China-based biotech developing ecoglutide (injectable GLP-1) and oral peptide formulations for metabolic diseases. Regional peer in the China cardiometabolic space with comparable GLP-1 development focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eccogene

Cardiometabolic Therapeuticseccogene.com

Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory diseases. Its pipeline includes an oral GLP-1 receptor agonist licensed to AstraZeneca plus wholly-owned THR-β and SSAO programs for obesity, type 2 diabetes, and MASH.

What Eccogene does

Eccogene, Inc. is a clinical-stage biopharmaceutical company founded in 2018 by drug-discovery veterans from Lilly China R&D and GlaxoSmithKline. Headquartered in Cambridge, Massachusetts with research operations in Shanghai's Zhangjiang district, Eccogene focuses on discovering and developing oral small molecule therapeutics for cardiometabolic and inflammatory diseases — principally obesity, type 2 diabetes, MASH/NASH, dyslipidemia, and osteoarthritis pain. The company's core technology platform is a translational small molecule discovery engine that targets metabolic disease pathways including GLP-1, THR-β, SSAO/VAP-1, GIP, and amylin, with design priorities of oral once-daily dosing, improved PK/PD and safety profiles, and combinability with GLP-1 receptor agonists.

The pipeline is anchored by ECC5004 (elecoglipron/AZD5004), an internally discovered, once-daily oral small molecule GLP-1 receptor agonist that has demonstrated best-in-class potential in preclinical and Phase 1 data and is now in AstraZeneca's hands for Phase 2b/3 development. Wholly-owned clinical assets include ECC4703, a selective liver-targeting THR-β full agonist in Phase 2a for MASH and as an adjunct to semaglutide in obesity (MIST trial), and ECC0509, a peripherally restricted SSAO/VAP-1 inhibitor in Phase 2a for MASH and osteoarthritis pain. Preclinical programs target GIP, amylin, and a unimolecular poly-agonist (UPA) engaging GLP-1R, GIPR, and amylin receptors.

Eccogene operates an asset-light licensing business model, monetizing its pipeline through upfront payments, development and regulatory milestones, and royalties from pharmaceutical partners rather than building its own commercial organization. The AstraZeneca license for ECC5004 generated a $185 million upfront in November 2023 and a $60 million milestone in October 2024, with up to $1.825 billion in additional potential milestones and tiered royalties; Eccogene retains co-development and co-commercialization rights in China. The company is funded by a syndicate of healthcare-focused venture investors including Delos Capital, Oriza Seed Capital, New Alliance Capital, and Zhangjiang Healthcare Venture Capital, and has secured multiple FDA IND clearances across its pipeline.

Eccogene firmographics

Firmographics
Name
Eccogene
Legal name
Eccogene, Inc.
Website
https://eccogene.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory diseases. Its pipeline includes an oral GLP-1 receptor agonist licensed to AstraZeneca plus wholly-owned THR-β and SSAO programs for obesity, type 2 diabetes, and MASH.
Ownership category
akta.pro rank

Eccogene industry classification

Industry
Product category
Cardiometabolic Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Small molecule therapeutics
  • Cardiometabolic drug discovery
  • Oral GLP-1 agonists
  • Metabolic disease treatments
  • Anti-obesity pharmaceuticals

Where Eccogene is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Eccogene business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Licensing and Milestone Payments: Eccogene generates revenue through licensing agreements with pharmaceutical partners, receiving upfront payments, milestone payments tied to clinical, regulatory, and commercial achievements, and tiered royalties on net product sales. The AstraZeneca deal for ECC5004 includes $185 million upfront, up to $1.825 billion in future milestones, and royalty payments.
  2. Series B Equity Financing: CNY 180 million (approximately $25 million) Series B financing co-led by New Alliance Capital and Zhangjiang Healthcare Venture Capital, with participation from Rockbleu Capital, YuFu Investment, Huajin Capital, Elikon Venture, Delos Capital, Oriza Seed Capital, and Qingsong Capital.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Eccogene product offering

Product offering

Core offering

Eccogene discovers and develops oral small molecule drug candidates for cardiometabolic and inflammatory diseases, with a pipeline targeting obesity, type 2 diabetes, MASH/NASH, dyslipidemia, and OA pain. Its lead asset ECC5004 (elecoglipron/AZD5004), an oral once-daily small molecule GLP-1 receptor agonist, has been exclusively licensed to AstraZeneca for global development and commercialization. The company also independently advances ECC4703 (THR-β full agonist), ECC0509 (SSAO inhibitor), and preclinical programs targeting GIP, amylin, and a unimolecular poly-agonist.

Differentiator

Problem solved

Functional benefit

Products and services

  • ECC5004 / Elecoglipron (AZD5004) Once-daily, low-dose oral small molecule GLP-1 receptor agonist discovered internally by Eccogene; best-in-class potential with favorable safety/tolerability and clinically meaningful weight reduction in Phase 1b. Licensed to AstraZeneca globally (all territories except China) for development and commercialization across obesity, type 2 diabetes, and related cardiometabolic indications; Eccogene retains co-development and co-commercialization rights in China.
  • ECC4703 β-selective, liver-targeting thyroid hormone receptor (THR-β) full agonist with once-daily oral dosing, designed for MASH/NASH, dyslipidemia, and weight management (including combination use with GLP-1 receptor agonists). Demonstrated superiority over partial agonist MGL-3196 in preclinical studies and favorable Phase 1 safety, PK/PD, and target engagement.
  • ECC0509 Highly selective, peripherally distributed small molecule inhibitor of SSAO/VAP-1 with minimal brain penetration, developed for NASH/MASH and osteoarthritis pain, with favorable safety and target engagement profiles demonstrated in Phase 1.
  • GIP Program (Small Molecule GIPR Agonist) Preclinical small molecule GIP receptor agonist program targeting metabolic diseases, part of Eccogene's broader pipeline exploring proven metabolic pathways beyond GLP-1.
  • Amylin Program (Small Molecule AmylinR Agonist) Preclinical small molecule amylin receptor agonist program targeting metabolic diseases, designed to complement GLP-1-based therapies for enhanced metabolic benefits.
  • UPA Program (Unimolecular Poly-agonist) Preclinical unimolecular poly-agonist that engages GLP-1R, GIPR, and Amylin receptors in a single molecular entity, designed to deliver enhanced metabolic benefits versus single-pathway agonists.

Companies that use Eccogene

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Eccogene technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Eccogene partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and minor.

  • AstraZenecaflagshipStrategic or Co-development Partner · 9 November 2023Eccogene entered an exclusive license agreement with AstraZeneca in November 2023 for ECC5004/AZD5004, an oral small molecule GLP-1 receptor agonist. AstraZeneca received exclusive global rights for development and commercialization in all territories except China, where Eccogene retains co-development and co-commercialization rights. Eccogene received $185 million upfront and is eligible for up to $1.825 billion in future clinical, regulatory, and commercial milestones, plus tiered royalties on net sales. AstraZeneca is advancing ECC5004 (now called elecoglipron or AZD5004) through Phase 2b and Phase 3 trials.
  • CSPC PharmaceuticalsminorStrategic or Co-development PartnerAstraZeneca has established collaborations with partners including Eccogene, CSPC Pharmaceuticals, the SOPHIA Consortium, FNIH, and Shanghai Institute of Materia Medica to advance next-generation therapies for obesity and type 2 diabetes.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Eccogene competitors and assessment

Company assessment

Direct peers

  • Structure Therapeutics: Clinical-stage biotech developing oral small molecule GLP-1 receptor agonists (GSBR-1290) for obesity and type 2 diabetes. Direct competitor in oral GLP-1 RA space with similar best-in-class positioning strategy.
  • Viking Therapeutics: Clinical-stage biotech developing VK2735 (oral and subcutaneous GLP-1/GIP dual agonist) for obesity. Comparable pipeline focus on oral and injectable cardiometabolic candidates with similar licensing/partnering strategy.
  • Terns Pharmaceuticals: Clinical-stage biotech developing TERN-601 (oral GLP-1 RA) and other oral small molecules for obesity. Direct peer in oral GLP-1 development with similar China-related operational footprint.
  • Madrigal Pharmaceuticals: Developed resmetirom (Rezdiffra), the first FDA-approved THR-β agonist for MASH. Directly relevant peer for Eccogene's ECC4703 THR-β agonist program targeting the same MASH/NASH indication.
  • Akero Therapeutics: Clinical-stage biotech developing efruxifermin (FGF21 analog) for MASH. Comparable peer in MASH/NASH therapeutics with similar Phase 2/3 development path and licensing economics potential.
  • 89bio: Clinical-stage biotech developing pegozafermin (FGF21 analog) for MASH. Comparable peer in MASH/NASH with similar clinical-stage positioning and licensing partnership potential.

Regional players

  • Innovent Biologics: China-based biopharmaceutical company developing mazdutide (IBI362), a GLP-1/glucagon dual agonist for diabetes and obesity. Regional peer in cardiometabolic space with comparable China commercial footprint and oral/injectable metabolic pipeline.
  • Sciwind Biosciences: China-based biotech developing ecoglutide (injectable GLP-1) and oral peptide formulations for metabolic diseases. Regional peer in the China cardiometabolic space with comparable GLP-1 development focus.

Broad incumbents

  • Pfizer: Large pharmaceutical company developing danuglipron, an oral small molecule GLP-1 RA for obesity and diabetes. Broad incumbent in the same oral GLP-1 space with massive commercialization capabilities competing with Eccogene's ECC5004.
  • Eli Lilly: Global pharmaceutical leader with orforglipron (oral GLP-1 RA) in late-stage development and established injectable franchise (semaglutide via Mounjaro/Zepbound competitor Novo Nordisk). Broad incumbent whose R&D lineage includes Eccogene's founders.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Eccogene social profiles

Digital presence

Eccogene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eccogene leadership team

Management profile

Number of profiles

Profiles11 records

Eccogene funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eccogene M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eccogene

What does Eccogene do?

Eccogene discovers and develops oral small molecule drug candidates for cardiometabolic and inflammatory diseases, with a pipeline targeting obesity, type 2 diabetes, MASH/NASH, dyslipidemia, and OA pain. Its lead asset ECC5004 (elecoglipron/AZD5004), an oral once-daily small molecule GLP-1 receptor agonist, has been exclusively licensed to AstraZeneca for global development and commercialization. The company also independently advances ECC4703 (THR-β full agonist), ECC0509 (SSAO inhibitor), and preclinical programs targeting GIP, amylin, and a unimolecular poly-agonist.

Is Eccogene a public or private company?

Eccogene is a private company. It is classified as venture growth investor backed and is currently operating.

When was Eccogene founded?

Eccogene was founded in 2018. It employs 11 to 50 people.

Where is Eccogene based?

Eccogene is headquartered in Cambridge, United States, in the North America region.

How does Eccogene make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are series B Equity Financing.

Who are Eccogene's main competitors?

Direct peers on record are Structure Therapeutics, Viking Therapeutics, Terns Pharmaceuticals, Madrigal Pharmaceuticals, Akero Therapeutics and 89bio. Regional players are Innovent Biologics and Sciwind Biosciences. Broad incumbents are Pfizer and Eli Lilly.

Does Eccogene have an API?

No public API is recorded for Eccogene.

What industry is Eccogene in?

Eccogene's product category is Cardiometabolic Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialEccogene To Present Preclinical Data Of Small Molecule Amylin And Calcitonin Receptor Agonist ECC1542 At Obesityweek® 2026Eccogene will present preclinical data on ECC1542, a small-molecule amylin and calcitonin receptor agonist, at ObesityWeek 2026 in National Harbor, Maryland, November 14-17. The company highlights its oral profile for potential monotherapy and combination therapies. The poster presentation is scheduled for November 14, 2026.Longevity.TechnologyEccogene earns $50m as AstraZeneca starts Phase 3 weight-loss pill trialsEccogene received a $50 million milestone payment from AstraZeneca after initiating global Phase 3 trials for elecoglipron, a GLP-1 agonist for cardiometabolic diseases. The trials include Embold and Eluminate studies, following positive Phase 2b results showing 11.8% weight loss at 36 weeks. Eccogene has earned $295 million to date under the license.BioSpaceEccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)Eccogene received a $50 million milestone payment from AstraZeneca for initiating the global Phase 3 program of elecoglipron, an oral GLP-1 agonist. The company has earned $295 million to date and remains eligible for future milestones and royalties. The Phase 3 program includes trials for obesity, type 2 diabetes, heart failure, and chronic kidney disease.FinancialContent Business PageEccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)Eccogene received a $50 million milestone payment from AstraZeneca for initiating the global Phase 3 program of elecoglipron. The company has earned $295 million to date under the collaboration and remains eligible for future milestones and royalties. The Phase 3 program includes trials for obesity, type 2 diabetes, heart failure, and chronic kidney disease.MarketScreenerRace to launch weight-loss pills heats up as smaller players advanceMultiple companies are racing to launch oral obesity drugs, with Kailera's drug showing up to 10.9% weight loss in a China trial. Novo Nordisk and Eli Lilly have approved oral GLP-1 pills, while others like Structure and AstraZeneca are advancing candidates. Wall Street is revising its $150 billion market forecast.MarketScreenerRace to launch weight-loss pill heats up as Novo wins UK approvalNovo Nordisk received UK approval for its oral weight-loss drug Wegovy, securing U.S. clearance in December ahead of Eli Lilly's orforglipron. The global market faces generic competition and price pressure, prompting Wall Street to rethink a $150 billion forecast. Multiple companies are racing to launch oral GLP-1 drugs.Business Wire BlogMultiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026Eccogene and AstraZeneca will present data on elecoglipron at ADA 2026, with Eccogene showing Phase 1b results and AstraZeneca presenting Phase 2b data from two global studies. The oral GLP-1 agonist is being developed for obesity and type 2 diabetes, with AstraZeneca holding global rights outside Greater China.AstrazenecaObesity and weight management: Transforming care through scienceAstraZeneca has outlined its approach to obesity and weight management research, emphasizing multi-pathway solutions targeting GLP-1, amylin, glucagon, and activin pathways to address the biological complexity of obesity as a chronic disease. The company highlights that nearly three billion people worldwide are affected by obesity or overweight, with over 60% having at least one obesity-related comorbidity, underscoring the urgent need for sustainable, long-term management options. AstraZeneca has established collaborations with partners including Eccogene, CSPC Pharmaceuticals, the SOPHIA Consortium, FNIH, and Shanghai Institute of Materia Medica to advance next-generation therapies for obesity and type 2 diabetes.openPR.comDiabetes Market: Rapid Increment Driven by Innovation by 2032 - DelveInsight | Eli Lilly and Company, Regor Pharma AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNovaDelveInsight released a diabetes market report projecting significant growth during the 2019–2032 forecast period, driven by rising disease prevalence and an expanding pipeline of therapeutic candidates. Several regulatory and corporate developments shaped the diabetes landscape: the FDA approved Merilog (insulin-aspart-szjj) as the first rapid-acting biosimilar to NovoLog in February 2025, while also lifting a clinical hold on vTv Therapeutics' cadisegliatin program and issuing a safety alert on smartphone-dependent diabetes devices. In parallel, Vertex Pharmaceuticals halted its VX-264 cell therapy development, Novo Nordisk filed a Citizen Petition regarding liraglutide, and Eton Pharmaceuticals acquired U.S. rights to Amglidia for neonatal diabetes treatment.BioSpaceEccogene Announces First Patient Enrolled in MIST Phase 2a Trial Evaluating ECC4703 as an Adjunct to Semaglutide for the Treatment of ObesityEccogene announced the enrollment of the first patient in its MIST Phase 2a clinical trial evaluating ECC4703 as an adjunct to semaglutide for treating obesity in approximately 160 adults. ECC4703 is an oral, once-daily selective thyroid hormone receptor-beta agonist designed to potentially enhance weight loss and reduce liver fat through a dual-mechanism approach combining GLP-1 therapy with liver-targeting metabolic modulation.